Skip to Main Content

Paper Details

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
J Am Heart Assoc
46
2016
Coronary Heart Disease, Lp-PLA2, Patients, Phospholipase A2, cardiovascular, cardiovascular death, coronary heart disease, darapladib, heart failure, lipoprotein-associated phospholipase A2, myocardial infarction, patients, stroke
Author NameAffiliation
Christopher P CannonBrigham and Women's Hospital, MA Harvard Clinical Research Institute
Robert A HarringtonStanford University
Emile R MohlerPerelman School of Medicine, University of Pennsylvania
  • 1 - 3

Datasets

Release 1.2